Researchers helping map brain cancer genome

February 23, 2012, University of Cincinnati

Fueled by the hope of finding better treatments, patients like Kenneth Jacques are helping medical science map the entire genetic sequence of a few types of brain tumors.

Those tumors include Grade 3 gliomas, an uncommon type of brain that struck Jacques in September 2011. At that time, the West Chester Township, Ohio, engineer and father of two made two decisions. One was to get well. The other was to give back by enrolling in the genetic sequencing study, also known as the Cancer Genome Atlas Trial, at the Brain Tumor Center at the University of Cincinnati (UC) Neuroscience Institute, a specialty center within UC Health.

As a participant in the study, Jacques donated tissue from his tumor to be used for genetic sequencing.

"Our goal is to out a tumor’s entire genome to identify potential areas at the molecular level that are abnormal and that could be targets for therapies of the future,” says Christopher McPherson, MD, a neurosurgeon with the UC Brain Tumor Center and Mayfield Clinic and director of the department of neurosurgery’s division of surgical neuro-oncology at the UC College of Medicine. "We are extremely interested in developing sophisticated drugs that target specific differences within cancer cells. As of now, we don’t have a lot of good treatments for patients with these particular tumors.”

The Cancer Genome Atlas Study, a project of the National Cancer Institute and the National Human Genome Research Institute, involves a network of institutions throughout the United States, including clinical sites, a specimen processing facility and genomic characterization centers.

McPherson, principal investigator of Cincinnati’s portion of the study, stresses that the search for targets in genetic or protein abnormalities is a very important step but only the earliest phase of discovery. "We have to identify the targets before we can identify the drugs to use,” he says.

"We send tissue specimens to NIH and don’t get the answers back right away. They have to study and process the tissue. But this study holds promise for the future. As abnormal areas are identified, treatments will be developed, and then we will be able to provide clinical trials.”

The Cancer Genome was launched in 2006 with a pilot study of three types of tumors: glioblastoma multiforme (a Grade 4 glioma), serious cystadenocarcinoma of the ovary and squamous cell carcinoma of the lung. Researchers hoped to learn whether such a comprehensive analysis would be feasible as well as beneficial. The pilot study was so successful that additional cancer types, including Grade 3 glioma, were added in 2010. The UC Brain Tumor Center began enrolling patients in 2011. 

"Glioma is a broad term that encompasses all of the tumors that come from the glial cell, a supporting cell in the brain,” McPherson says. "Any of the glial cells can become tumors. Astrocytoma, ependymoma, oligodendroglioma: All are different types of gliomas. Gliomas are graded on a scale of one to four.”

A Grade 4 glioma, the most malignant, is a glioblastoma multiforme, so named because each individual cancer can include many different genetic forms and aberrations.

"Research has enabled us to see the step-wise progression of mistakes that occur as a tumor evolves from a low-grade glioma to a Grade 3 to a glioblastoma,” McPherson says. "We have already identified some of those errors; but these discoveries have not been as fruitful as we would wish. We hope that by mapping entire genome we will find more answers for potential treatment.”

Jacques’ symptoms began as mini seizures, "brief spells where I started to feel like I was going to pass out, but I never did.” Shortly after an incident in which he was supposed to talk to his son about breakfast but instead began talking about work, he called the doctor. An MRI revealed the tumor, an anaplastic astrocytoma, in an "eloquent” area in the left side of his brain, near the areas responsible for speech.

After discussing Jacques’s situation at the weekly Multidisciplinary Tumor Board Conference, the Brain Tumor Center team settled on a strategy that including careful three-dimensional mapping of the tumor as well as the critical functional centers and electrical pathways in Jacques’ brain. McPherson then operated, removing as much of the tumor as possible, while Jacques was awake. Surgery was followed by 33 radiotherapy treatments at Precision Radiotherapy Center in West Chester and chemotherapy.

Jacques says he was informed about ongoing clinical trials around the time of his surgery. "I accepted the opportunities as a way to help others,” he says. "That is a part of who I am.”

"Basically, the importance of research is what we can develop for the future,” McPherson says. "Mr. Jacques is allowing his tissue to be studied and looked at for treatment that will hopefully benefit him—but if not him, then future generations. Every person with should be involved in research because we still don’t have good treatment options.”

Explore further: Lifting the fog: Finding by neuro-oncologist could help eliminate 'chemo brain'

Related Stories

Lifting the fog: Finding by neuro-oncologist could help eliminate 'chemo brain'

September 29, 2011
After receiving her medical degree in her homeland of Romania, Dr. Daniela Bota came to the U.S. to earn a doctorate in molecular biology to better understand why people develop neurodegenerative diseases such as Alzheimer's.

Minimizing side effects from chemoradiation could help brain cancer patients live longer

April 19, 2011
Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. ...

Online archive to link tumor scans, genetic data

June 24, 2011
The National Cancer Institute (NCI) has chosen Washington University School of Medicine in St. Louis to create an innovative, Internet-accessible database of millions of cancer images.

Recommended for you

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.